$Kala制药(KALA)$ KALA Kala recent selloff brings attractive entry point, says JPMorgan
JPMorgan analyst Christopher Neyor says the recent pullback in shares of Kala Pharmaceuticals provides an attractive entry point. With the company's lead asset Eysuvis in an early stage product launch, Neyor sees a "highly favorable" risk/reward for the shares. Kala has a "significant" dry eye market opportunity with greater than $750M in potential long-term peak sales and a "strong sales ramp" in the second half of 2021 which should "de-risk" the company's dry eye commercialization plans, Neyor tells investors in a research note.